Method for evaluating photoaging of skin, comprising measuring amount of 9-HODE
By measuring the amount of 9-HODE in the skin and analyzing lifestyle habits and ultraviolet exposure time, the problem of photoaging evaluation was solved, and the accuracy of photoaging was achieved by screening and adjusting 9-HODE agents.
Patent Information
- Application Number
- CN202410614895.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-17
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to effectively evaluate and predict photoaging, especially in the youth to middle age, with fewer appearance changes, and it is difficult to accurately evaluate the degree of photoaging and potential risks of the skin through appearance changes.
By measuring the amount of 9-HODE in the skin and lipomics analysis, combining living habits and UV exposure time, the degree of photoaging was evaluated, and agents that regulate the amount or function of 9-HODE were screened to regulate photoaging.
Accurate evaluation and prediction of photoaging is achieved, the degree and possibility of photoaging can be evaluated, and the photoaging process is regulated by agents that regulate 9-HODE.
Smart Images

Figure CN119064602A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for evaluating photoaging of the skin by measuring the amount of 9-HODE, a physiologically active lipid that is found in high amounts in the skin of elderly people who have been exposed to ultraviolet rays for many years, through lipidomic analysis. In addition, in another embodiment of the present invention, it also relates to a method for screening a component that can regulate photoaging based on the amount of 9-HODE or the function of a receptor to which 9-HODE binds. Background Art
[0002] Photoaging refers to aging caused by the action of sunlight. It is generally believed that photoaging is essentially different from natural aging caused by aging. The main cause of photoaging is ultraviolet rays, which cause changes in appearance such as dullness, spots, wrinkles, and sagging. Although such changes in appearance also occur in natural aging caused by aging, the impact of changes in appearance caused by ultraviolet rays is greater. These changes in appearance promote melanin production, changes in collagen fibers / elastic fibers, inflammation, etc. in the skin exposed to ultraviolet rays, and affect the skin properties in a complex way. It is generally believed that by the age of 18, about half of the ultraviolet rays that are exposed in a lifetime will be exposed. The effects of ultraviolet rays such as sunburn will occur immediately. On the other hand, dullness, spots, wrinkles, sagging, etc. related to photoaging do not occur immediately, but appear over time. Photoaging is evaluated specifically by changes in appearance, but on the other hand, it is difficult to accurately evaluate potential photoaging from changes in appearance.
[0003] On the other hand, 9-hydroxyoctadecadienoic acid is known as a metabolite of linoleic acid and has been studied as a biomarker for several diseases and aging. Specifically, it is known to be a biomarker in a method for diagnosing a lifestyle that can delay and / or avoid chronic inflammatory disorders associated with aging (Patent Document 1: Japanese Patent Publication No. 2015-514203). In addition, it has also been reported as a biomarker for diseases associated with the contact activation system (Patent Document 2: Japanese Patent Publication No. 2019-534446) or refractory nocturnal frequent urination / nocturnal polyuria (Patent Document 3: Japanese Patent Publication No. 2019-066239). In addition, it is reported that 9-HODE itself also has physiological activity, and it is reported that it activates peroxisome proliferator-activated receptor γ (PPARγ) and increases the transcription of such receptor-inducible genes (Non-Patent Document 1: Nat Struct Mol Biol. 2008 Sep; 15 (9): 924-931).
[0004] Prior art literature
[0005] Patent Literature
[0006] Patent Document 1: Japanese Patent Application No. 2015-514203
[0007] Patent Document 2: Japanese Patent Application No. 2019-534446
[0008] Patent Document 3: Japanese Patent Application Publication No. 2019-066239
[0009] Non-patent literature
[0010] Non-patent literature 1: Nat Struct Mol Biol. 2008 Sep; 15(9): 924-931 Summary of the invention
[0011] Problems to be solved by the invention
[0012] Although photoaging progresses through various mechanisms, the prevention measures for photoaging are often insufficient because it has little effect on the appearance of young to middle-aged people. Therefore, it is required to develop a method that can appropriately evaluate the degree of photoaging of the skin, the possibility of onset of photoaging, or predict the future by evaluating photoaging that does not appear on the outside.
[0013] Means for solving problems
[0014] In view of the above problems, lipidomic analysis of skin of various age groups was conducted, and as a result, physiologically active lipids that are present in large amounts only in stratum corneum samples obtained from people with a long history of ultraviolet exposure were found. Various analyses were conducted on such physiologically active lipids, and as a result, surprisingly, substances involved in photoaging of the skin were found, and it was found that photoaging can be evaluated by measuring the amount of such physiologically active lipids, thereby completing the present invention.
[0015] The present invention therefore relates to the following solutions.
[0016] [1] A method for evaluating photoaging of the skin, characterized by measuring the amount of 9-HODE in the skin.
[0017] [2] The method according to item 1, wherein the photoaging of the skin is at least one selected from the group consisting of dullness, spots, chronic inflammation, wrinkles, decreased skin moisture retention function, and sagging.
[0018] [3] A method for screening photoaging regulators, characterized by selecting a drug that can regulate the production amount or function of 9-HODE derived from the skin.
[0019] [4] The method according to item 3, wherein the photoaging of the skin is at least one selected from the group consisting of dullness, spots, chronic inflammation, wrinkles, decreased skin moisture retention function and sagging.
[0020] [5] The screening method according to item 3 or 4, comprising the following steps:
[0021] A step of culturing skin cells with a culture medium containing a candidate ingredient;
[0022] A step of measuring the amount of 9-HODE in cultured skin cells; and
[0023] The step of comparing the measured 9-HODE amount with the 9-HODE amount of the control,
[0024] In the case where the amount of 9-HODE is increased or decreased, candidate ingredients are screened as photoaging regulators.
[0025] [6] The method according to item 3 or 4, wherein the operation of selecting an agent capable of regulating the production amount or function of the above-mentioned 9-HODE is an operation of measuring the increase or decrease in the expression of at least one protein or gene selected from IL1A, IL1B, IL6, IL8, GM-CSF, DKK1, COL1A1, COL3A1, MMP1, MMP3, VCAN (versican) and DCN (decorin) caused by the addition of 9-HODE.
[0026] [7] The screening method according to item 6, comprising the following steps:
[0027] A step of culturing skin cells using a culture medium containing a candidate ingredient and 9-HODE;
[0028] A step of measuring the amount of at least one protein selected from the group consisting of IL1A, IL1B, IL6, IL8, GM-CSF, DKK1, COL1A1, COL3A1, MMP1, MMP3, VCAN and DCN or the expression level of the gene in the cultured skin cells or the culture supernatant; and
[0029] a step of comparing the amount of protein or the expression level of gene in cells or culture supernatant cultured in a medium not containing the candidate component with the amount of protein or the expression level of gene in cells or culture supernatant cultured in a medium containing the candidate component as a control,
[0030] When the amount of protein or the expression level of gene in cells or culture supernatants cultured with a medium containing the candidate ingredient increases or decreases, the candidate ingredient is screened as a photoaging regulator.
[0031] [8] A photoaging inhibitor comprising an ingredient that inhibits the production amount or function of 9-HODE.
[0032] [8-2] Use of a component that inhibits the production amount or function of 9-HODE for the production of a photoaging inhibitor.
[0033] [9] The photoaging inhibitor according to item 8, wherein the component that regulates the function of 9-HODE is a GPR132 (G2A) antagonist.
[0034] [9-2] The use according to item 8-2, wherein the component that regulates the function of 9-HODE is a GPR132 (G2A) antagonist.
[0035]
[10] The photoaging inhibitor according to any one of items 8 to 9, wherein the component that regulates the amount of 9-HODE produced or the function thereof is a tea leaf extract or a Potentilla pubescens root extract.
[0036] [10-2] The use according to item 8-2 or 9-2, wherein the component that regulates the production amount or function of 9-HODE is a tea leaf extract or a Potentilla pubescens root extract.
[0037]
[11] A bone density improving agent comprising a component that regulates the production amount or function of 9-HODE, or 9-HODE.
[0038] [11-2] A component for regulating the production amount or function of 9-HODE, or use of 9-HODE in the manufacture of a bone density improving agent.
[0039] Effects of the Invention
[0040] Photoaging can be evaluated by measuring 9-HODE in the skin, which is an indicator of photoaging of the skin. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 This graph shows the number of wrinkles of subjects of each age group divided into low and high score groups of UV score (lifestyle F) based on their lifestyle habits. For those in their 20s, there is no difference between the low and high score groups ( Figure 1 A), on the other hand, for those in their 50s, the high-score group showed significantly more wrinkles than the low-score group ( Figure 1 B).
[0042] Figure 2 The subjects of each age group are divided into low- and high-score groups according to the UV exposure time score (exposure time F), and the skin brightness (L * ) is a graph comparing each age group. For those in their 20s, there was no difference between the low- and high-scoring groups in both the non-exposed part (arm) and the exposed part (cheek) ( Figure 2A), on the other hand, for those in their 50s, there was no difference between the low-score group and the high-score group for the non-exposed part (arm), but for the exposed part (cheek), the skin brightness (L * ) significantly reduced ( Figure 2 B).
[0043] Figure 3 This is a graph showing the relationship between the stratum corneum moisture content in the exposed area (cheek) and the exposure time F of a subject in his twenties and a subject in his fifties.
[0044] Figure 4 The graph shows the relationship between the exposure time F and the skin viscoelasticity in the non-exposed part (arm) and the exposed part (cheek) of a subject in his 20s and a subject in his 50s.
[0045] Figure 5 (A) shows the amount of 9-HODE extracted from the stratum corneum of the epidermis of subjects classified by exposure time F into a low-scoring group in their 20s, a high-scoring group in their 20s, a low-scoring group in their 50s, and a high-scoring group in their 50s. Figure 5 (B) shows the amount of 9-HODE extracted from the stratum corneum of the epidermis of the subjects in the low-scoring group in their 20s, the high-scoring group in their 20s, the low-scoring group in their 50s, and the high-scoring group in their 50s classified by lifestyle F.
[0046] Figure 6 The graphs show the changes in expression of (A) IL-8, (B) IL-6, (C) GM-CSF, (D) IL-1B, (E) IL-1A, and (F) DKK1 after adding 9-HODE to cultured keratinocytes.
[0047] Figure 7 Graphs showing changes in expression of (A) COL1A1, (B) COL3A1, (C) MMP-1, (D) MMP-3, (E) DCN, (F) VCAN, (G) IL-8, and (H) IL-1A after addition of 9-HODE to cultured fibroblasts.
[0048] Figure 8 The graphs show the effects of various drugs on changes in gene expression when 9-HODE is added to cultured keratinocytes (DKK1 (A) and GM-CSF (B)).
[0049] Fig. 9 The graphs show the effects of various drugs on changes in gene expression when 9-HODE is added to cultured fibroblasts (COL1A1 (A), COL3A1 (B), DCN (C), and VCAN (D)). DETAILED DESCRIPTION
[0050] The present invention relates to a method for evaluating the degree or possibility of onset of skin photoaging, comprising measuring the amount of 9-hydroxyoctadecadienoic acid (hereinafter referred to as 9-HODE) in the skin of a subject, which is an indicator of skin photoaging.
[0051] 9-HODE is a fatty acid having the following formula.
[0052]
[0053] The carbon at position 9 is asymmetric, and includes optical isomers of S type: 9-(S)-hydroxy-10(E),12(Z)-octadecadienoic acid and R type: 9-(R)-hydroxy-10(E),12(Z)-octadecadienoic acid. Optical isomers can be separated and measured using a chiral column or the like, but can also be measured without separation. 9-HODE is known as a metabolite of linoleic acid, and it is believed that it is produced in cells when linoleic acid is placed under oxidative stress.
[0054] 9-HODE is known to have physiologically active effects through its effects on G protein-coupled receptors (GPCRs) and peroxisome proliferator-activated receptor γ (PPARγ). As a G protein-coupled receptor, it is particularly known to act through GPR132 (also known as G2A). For epidermal keratinocytes, 9-HODE can promote the production of inflammatory cytokines and melanocyte stimulating factors. Examples of such inflammatory cytokines and melanocyte stimulating factors include IL-8, IL-6, GM-CSF, IL-1A, IL-1B, DKK-1, IL-1A ( Figure 6 ). Therefore, 9-HODE accumulates, causing inflammation of the epidermis. Inflammation of the epidermis can lead to increased melanin production. Since 9-HODE is originally a melanocyte, melanin accumulation occurs, leading to spots and pigmentation. It is known that DKK-1, whose expression is promoted by 9-HODE, is expressed in large quantities in bone tissue. It is known that it inhibits bone formation by blocking Wnt signals, and can promote bone formation by reducing its expression.
[0055] 9-HODE has the effect of inhibiting the amount of collagen fibers in fibroblasts. As an example, 9-HODE reduces the production of collagen in fibroblasts ( Figure 7 (A), (B)), on the other hand, the expression of matrix metalloproteinases that promote the degradation of collagen fibers is increased ( Figure 7(C), (D)). Through the action of 9-HODE, the expression of collagens such as COL1A1 and COL3A1 is reduced, and the expression of matrix metalloproteinases such as MMP-1 and MMP-3 is increased. In addition, through the action of 9-HODE, the expression of proteoglycans such as decorin (DCN) and versican (VCAN) is reduced. Furthermore, through the action of 9-HODE, the expression of inflammatory mediators such as IL-8 and IL-1A is increased. In this way, through the action of 9-HOPE, inflammation is promoted, the amount of collagen fibers is reduced, and proteoglycans are reduced, thereby leading to the formation of wrinkles.
[0056] Photoaging refers to aging caused by the action of sunlight. It is generally believed that photoaging is essentially different from aging caused by aging, and is proportional to the duration and intensity of exposure to ultraviolet rays. It is generally believed that about half of the lifetime exposure to ultraviolet rays will be received by the age of 18, and its effects will appear at advanced ages. The main cause of photoaging is ultraviolet rays, which cause changes in appearance such as dullness, spots, wrinkles, and sagging, as well as changes in the skin's interior such as chronic inflammation, promotion of melanin production, and reduction of collagen fibers. In addition, the inventors found a correlation between the amount of moisture in the stratum corneum in the exposed area (cheeks) of subjects in their 50s and the exposure time F ( Figure 3 ). It is thus shown that as changes in the skin caused by photoaging, a decrease in the skin's moisture retention function can be cited. The above-mentioned changes in appearance occur due to changes in the skin caused by ultraviolet rays. The changes in appearance caused by photoaging are rare in young to middle-aged people, and it is difficult to evaluate photoaging from appearance. In addition, attempts have been made to capture changes in chronic inflammation, melanin production promotion, and collagen fiber reduction in the skin, but these changes are not necessarily sufficient for appropriate evaluation of photoaging. In the present invention, photoaging can be evaluated by using the amount of 9-HODE that affects the mechanism of action of photoaging as an indicator. The photoaging evaluated by the present invention is at least one symptom selected from dullness, spots, chronic inflammation, wrinkles, decreased skin moisture retention function and sagging, or a combination thereof. Using the results of the evaluation of photoaging of the present invention, the degree of photoaging, that is, the degree of progression, can be determined. Photoaging has little effect on appearance in young to middle-aged people, but if it becomes a certain age, such as over 40 years old, the effect on appearance suddenly appears, so by evaluating photoaging in young to middle-aged people, the possibility of onset of photoaging in the future can be determined.
[0057] The amount of 9-HODE in the skin can be determined in the collected skin sample. The skin sample is a sample of the epidermis or dermis, more preferably an epidermis sample, in particular a stratum corneum sample. The epidermis sample can be obtained by a method known in the art, and as an example, can be prepared by collecting the epidermis stratum corneum with a stripped epidermis or collecting the epidermis with a dispase or a heated epidermis. The prepared epidermis sample can be provided to a lipid analysis method known in the art to analyze lipids. As a lipid analysis method, as an example, the lipids contained in the epidermis sample are extracted with a fat-soluble solvent, and the extracted lipids are provided for separation and analysis. As a fat-soluble solvent, acetone, ethanol, methanol, etc. can be used. The extracted lipids are then separated and analyzed by chromatography and capillary electrophoresis (CE). After separation, lipid analysis can be performed in combination with NMR and mass spectrometry (MS). As a chromatogram for separating lipids, gas chromatography (GC), liquid chromatography (LC), and supercritical fluid chromatography (SFC) can be used. As chromatography combined with mass spectrometry, in particular, gas chromatography-mass spectrometry (GC / MS), liquid chromatography-mass spectrometry (LC / MS, LC / MS / MS), and supercritical fluid chromatography-mass spectrometry (SFC / MS) can be used.
[0058] The results of lipidomics analysis showed that 9-HODE was present at 0.01 to 10 pg / μg protein in the skin, especially in the stratum corneum samples. It was shown that 9-HODE was significantly increased in the elderly group with high lifestyle F based on lifestyle habits and the elderly group with high exposure time F, which was quantified based on the ultraviolet exposure time ( Figure 5 ). Therefore, regarding the threshold value when 9-HODE is used as an indicator, a person skilled in the art can set it appropriately, but as an example, when the epidermal sample contains 1.5 pg / μg protein or more, preferably 2 pg / μg protein or more 9-HODE, it can be determined that photoaging is progressing. The risk of onset of photoaging can be estimated by considering the amount of 9-HODE and the part of the skin measured.
[0059] The UV score based on lifestyle habits can be determined by the answers to the questions about lifestyle habits related to UV avoidance. As an example, the score can be calculated by the answers to at least one of the following questions, or a combination thereof, divided into multiple stages. As an example, the score can be calculated by the answers divided into 2 to 10 stages, such as 3 stages, 4 stages, or 5 stages. As an example, the score can be calculated by the answers to the questions in 3 stages.
[0060] 1) Avoid sunlight
[0061] 2) Whether there is any experience of sun exposure
[0062] 3) Whether the departmental event / private event is held outdoors
[0063] 4) Whether sunscreen is used
[0064] 5) Whether hats / parasols are worn
[0065] The above questions can also be answered by age group. The age groups can be appropriately selected, and as an example, they can be divided into 0 to 11 years old (infant to school-age children), 12 to 17 years old (adolescence), 18 to 29 years old (youth), 30 to 44 years old (middle age), 45 years old to present, and the past year.
[0066] Photoaging, in particular photoaging based on skin brightness and / or wrinkles, can be evaluated based on a lifestyle-based UV score determined by responses to at least one of the above-mentioned lifestyles related to UV avoidance, or a combination thereof. Such a UV score may also be referred to as a lifestyle factor (lifestyle F).
[0067] Regarding the ultraviolet exposure time score, it can be divided by age, and for outdoor activities, the score can be calculated from the answers obtained by dividing into 2 to 10 stages, such as 3 stages, 4 stages, or 5 stages. As an example, it can be divided into 0 to 11 years old (infant to school-age period), 12 to 17 years old (adolescence), 18 to 29 years old (youth), 30 to 44 years old (middle age), 45 years old to the present, and the last year, and the score can be calculated from the answers obtained by dividing into 5 stages. Based on the ultraviolet exposure time score determined by the answer to the inquiry about ultraviolet exposure, photoaging, especially photoaging based on skin brightness and / or wrinkles, can be evaluated. Such an exposure time score can also be called an exposure time factor (exposure time F).
[0068] Photoaging can be evaluated based on the UV score and / or UV exposure time score based on lifestyle habits. The subjects in each age group can be divided into a high score group and a low score group based on the UV score based on lifestyle habits (lifestyle F) and the UV exposure time score (exposure time F), respectively. The high score group and the low score group can be appropriately classified. As an example, the upper 50% can be determined as the high score group, and the lower 50% can be set as the low score group.
[0069] In a further embodiment of the present invention, a method for screening photoaging regulators is provided, characterized in that an agent capable of regulating the production or function of 9-HODE derived from the skin is selected. The selection of agents regulating the production or function of 9-HODE can be performed by directly measuring the amount of 9-HODE, by measuring the activity of GPR132 (G2A) as a receptor of 9-HODE, or by measuring the result of activation of the receptor of 9-HODE, the expression amount of the gene whose expression is increased, or the amount of the translated protein.
[0070] GRP132 (G2A), a receptor for 9-HODE, can bind to various fatty acids such as linoleic acid metabolites, 13-HODE, arachidonic acid metabolites, 5-HETE, 12-HETE, and 15-HETE. GRP132 bound to specific fatty acids changes the expression of specific genes and the amount of proteins according to the cell type. For example, for keratinocytes, it enhances the secretion of cytokines such as IL-6, IL-8, and GM-CSF (Prostaglandins & Other LipidMediators, Volume 89, Issues 3-4, September 2009, Pages 66-72). Therefore, as an indicator in the screening method for photoaging regulators, the expression level or protein level of at least one gene selected from IL1A, IL1B, IL6, IL8, GM-CSF, DKK1, COL1A1, COL3A1, MMP1, MMP3, VCAN, and DCN can be used.
[0071] The screening method of the present invention more specifically comprises the following steps:
[0072] A step of culturing skin cells with a culture medium containing a candidate ingredient;
[0073] A step of measuring the amount of 9-HODE in cultured skin cells; and
[0074] The step of comparing the measured 9-HODE amount with the 9-HODE amount of the control,
[0075] In the case where the amount of 9-HODE increases or decreases, the candidate component can be selected as a photoaging regulator. In the case where the amount of 9-HODE decreases compared to the amount of 9-HODE in the control, the candidate component can be selected as a photoaging inhibitor. In addition, in the case where the amount of 9-HODE increases compared to the amount of 9-HODE in the control, the candidate component can be selected as a photoaging accelerator.
[0076] In other embodiments, the screening method of the present invention is to select candidate components that affect the interaction between 9-HODE and its receptor GRP132 (G2A). For such a screening method, as a screening index, the amount of at least one protein selected from IL1A, IL1B, IL6, IL8, GM-CSF, DKK1, COL1A1, COL3A1, MMP1, MMP3, VCAN, DCN or the amount of its gene expression can be used. More specifically, such a screening method includes, for example, the following steps:
[0077] The step of culturing skin cells in a medium containing the candidate ingredient and 9-HODE,
[0078] A step of measuring the amount of at least one protein selected from the group consisting of IL1A, IL1B, IL6, IL8, GM-CSF, DKK1, COL1A1, COL3A1, MMP1, MMP3, VCAN, and DCN, or the gene expression level thereof in the cultured skin cells; and
[0079] a step of comparing the measured amount of the at least one protein or the gene expression level thereof with the amount of the at least one protein or the gene expression level thereof in a control,
[0080] When the amount of at least one protein or the gene expression level thereof is increased or decreased, a candidate ingredient can be screened as a photoaging regulator.
[0081] When the amount of at least one protein or its gene expression is reduced compared with the amount of at least one protein or its gene expression in the control, the candidate component can be selected as a photoaging inhibitor. In addition, when the amount of at least one protein or its gene expression is increased compared with the amount of at least one protein or its gene expression in the control, the candidate component can be selected as a photoaging accelerator.
[0082] The control refers to the case where the experiment is performed under the same conditions as the experiment except that the candidate component is not added, and the measurement is performed. The experiment for the control may be performed in parallel, or may be performed in advance and the threshold value may be set based on the measurement value in the control.
[0083] The candidate components used in the screening method of the present invention can use any library of cosmetic raw materials, food raw materials, pharmaceutical raw materials, etc. As such a library, a compound library, an extract library, etc. can be used. The compounds and extracts contained in each library can use commercially available compounds and extracts, or synthetic compounds and prepared extracts can be used.
[0084] In other embodiments of the present invention, there are also provided photoaging inhibitors containing components that inhibit the production amount or function of 9-HODE. The photoaging inhibitor may also be referred to as a wrinkle inhibition or improvement agent, a relaxation inhibition or improvement agent, a spot inhibition or improvement agent, a dullness inhibition or improvement agent, or a skin moisture retention function maintenance or improvement agent. In still further other embodiments, there may be provided an osteogenesis promoter or bone density improver, which is characterized by containing a component that enhances the production amount or function of 9-HODE, or 9-HODE. Such an osteogenesis promoter or bone density improver can be used as a therapeutic agent for rheumatism, osteoporosis, fractures, etc. The administration route can be arbitrary, and it can be administered by commonly used methods such as intramedullary, intramuscular, subcutaneous, oral, transdermal, intravenous administration, etc. By inhibiting the expression of DKK1 by 9-HODE, an action related to such osteogenesis is produced.
[0085] As a component for regulating the function of 9-HODE, a GPR132 (G2A) antagonist can be cited. The component for regulating the production amount or function of 9-HODE can be selected by the screening method of the present invention. In still further other embodiments, as a component for regulating the production amount or function of 9-HODE, a tea extract or a Potentilla anserina root extract can be cited.
[0086] The tea extract is an extract obtained by solvent extraction from the leaves of the tea tree (Camellia sinensis (L.) Kuntze) widely distributed in South Asia, East Asia, and Southeast Asia. In the full ingredient label of cosmetics specified by the Japan Cosmetic Industry Association and the international label using the INCI name (International Nomenclature of Cosmetic Ingredients), it is represented by the name / INCI name: Tea Leaf Extract / CAMELLIA SINENSIS LEAF EXTRACT. It can be prepared by using water, alcohol, or a mixed solvent of any ratio thereof, such as 10:90 to 90:10, preferably 30:70 to 70:30, and more preferably 50:50 as the solvent for extraction. As the alcohol, ethanol, glycerin, butylene glycol, or propylene glycol can be used. More preferably, it can be extracted by a mixed solution of water and ethanol or water and 1,3-butylene glycol in any ratio, such as a mixed solution of 10:90 to 90:10, preferably 30:70 to 70:30, and more preferably 50:50. The tea extract contains various physiologically active substances such as catechins, caffeine, and theanine, and has various physiological effects represented by antioxidant effects. The tea extract is formulated in cosmetics, quasi-drugs, or drugs at a concentration of 0.00001% to 30%, more preferably 0.0001% to 10%.
[0087] Potentilla tormentilla root extract is an extract obtained by solvent extraction from the root of Potentilla tormentilla Schrk, which is widely distributed in Europe. In the designation name / INCI name recorded using the above-mentioned international designation name, it is represented by POTENTILLA ERECTA ROOT EXTRACT. It can be prepared by using water, alcohol, or a mixed solvent thereof as a solvent for extraction. It can be prepared by using water, alcohol, or a mixed solvent thereof in any ratio, such as 10:90 to 90:10, preferably 30:70 to 70:30, and more preferably 50:50, as a solvent for extraction. As alcohol, ethanol, glycerol, butylene glycol, and propylene glycol can be used. More preferably, it can be extracted by a mixture of water and ethanol or water and 1,3-butanediol in any ratio, for example, a mixture of 10:90 to 90:10, preferably a mixture of 30:70 to 70:30, and more preferably a mixture of 50:50. Potentilla root extract is used as a folk medicine as an antidiarrheal, hemostatic, and oral medicine, and is known to inhibit the production of vascular endothelial growth factor (VEGF-A). Potentilla root extract is mixed with cosmetics, quasi-drugs, or drugs at a concentration of 0.00001% to 30%, more preferably 0.0001% to 10%.
[0088] The component that inhibits the production amount or function of 9-HODE of the present invention, or the photoaging inhibitor, spot inhibitor, wrinkle inhibitor or improver, sagging inhibitor or improver, spot inhibitor or improver, dullness inhibitor or improver, and skin moisture retention function maintenance or improver can be used interchangeably, and can be mixed with cosmetics, medicines or quasi-drugs, respectively, and can also be mixed with foods such as nutritional supplements such as supplements. These agents can be administered orally or non-orally, such as transdermally. In the case of transdermal administration, it can be prepared as a skin external preparation. As long as the skin external preparation can be applied to the skin, there is no particular limitation, and any dosage form such as a solution, emulsion, solid, semi-solid, powder, powder dispersion, water-oil two-layer separation, water-oil-powder three-layer separation, ointment, gel, aerosol, mousse, stick, etc. can be used. In the case of being prepared as a skin external preparation, bases and excipients commonly used for skin external preparations, such as preservatives, emulsifiers, pH adjusters, etc., can be used. When mixed with cosmetics, it can be mixed with facial or body cosmetics such as lotions, emulsions, beauty essences, creams, lotions, masks, essences, gels, foundations, base makeup, concealers, and bath preparations, etc. By using cosmetics, drugs, and quasi-drugs containing the ingredients of the present invention, photoaging can be improved, alleviated, prevented, or treated by regulating the amount of 9-HODE produced or its function.
[0089] The concentration of the photoaging inhibitor of the present invention can be arbitrarily selected from the perspective of exerting the desired effect, the reduction or inhibition of photoaging, or the inhibitory effect of the progression or onset of photoaging. From the perspective of mixing as a skin external preparation, the extract involved in the present invention can be mixed at 0.0005% to 0.5%. From the perspective of fully exerting the effect, it is preferably mixed at 0.001% or more, and more preferably at 0.005% or more. From the perspective of avoiding strong odor, it is preferably mixed at 0.1% or less, and more preferably at 0.05% or less.
[0090] All documents mentioned in this specification are incorporated into this specification by reference in their entirety.
[0091] The embodiments of the present invention described below are for illustration purposes only and do not limit the technical scope of the present invention. The technical scope of the present invention is limited only by the description of the claims. Without exceeding the purpose of the present invention, changes of the present invention may be made, for example, addition, deletion and replacement of the constituent elements of the present invention.
[0092] Example 1
[0093] Example 1: Questionnaire Survey
[0094] (1) UV score based on lifestyle habits (Lifestyle F)
[0095] 105 subjects in their 20s and 88 subjects in their 50s who had no smoking history were asked about their past measures based on the following lifestyle habits, and responses were obtained in three stages:
[0096] 1) Avoid sunlight
[0097] 2) Whether there is any experience of sun exposure
[0098] 3) Whether the departmental event / private event is held outdoors
[0099] 4) Whether sunscreen is used
[0100] 5) Whether hats / parasols are worn
[0101] The case where countermeasures against ultraviolet rays were taken was scored as 1 point, the case where no countermeasures were taken was scored as 3 points, and the intermediate points were scored as 2 points.
[0102] When obtaining the answers, the subjects' past was divided into the following age groups and the answers were obtained separately:
[0103] 1) 0-11 years old
[0104] 2) 12 to 17 years old
[0105] 3) 18-29 years old
[0106] 4) 30 to 44 years old
[0107] 5) 45 years old to present
[0108] 6) Last year
[0109] The scores of the answers to each question were totaled to find the UV score based on lifestyle habits. The top 25 UV scores in each age group were set as the high score group, and the bottom 25 UV scores were set as the low score group.
[0110] The skin measurement and stratum corneum collection were carried out in a constant temperature and humidity chamber (22°C, 45%). Before the skin measurement and stratum corneum collection, the face was washed and acclimatized in the constant temperature and humidity chamber for 20 minutes.
[0111] The subjects were subjected to wrinkle replicas using the replica agent SILFLO (Monaderm), and the number of wrinkles was measured using the reflectance replica analysis system ASA-03RXD (Ashe, Japan). The subjects were divided into low-score and high-score groups based on the UV score of their lifestyle. The number of wrinkles was compared for each age group. The results showed that there was no difference between the low-score group and the high-score group in the 20s ( Figure 1 A), on the other hand, for those in their 50s, the number of wrinkles in the high-score group was significantly greater than that in the low-score group ( Figure 1 B) This result shows that the changes in appearance caused by photoaging are not obvious in the younger group, indicating that photoaging can be appropriately evaluated through questionnaires related to lifestyle habits.
[0112] (2) UV exposure time fraction (exposure time F)
[0113] 105 subjects in their 20s and 88 subjects in their 50s who had no smoking history were asked about their exposure to ultraviolet rays in the following age groups, and responses were obtained in five levels:
[0114] 1) 0-11 years old
[0115] 2) 12 to 17 years old
[0116] 3) 18-29 years old
[0117] 4) 30 to 44 years old
[0118] 5) 45 years old to present
[0119] 6) Last year
[0120] The case with the least exposure time to ultraviolet rays was set to 1 point, the case with the longest exposure time was set to 5 points, and the intermediate points were set to 2 to 4 points. The scores of the answers to each question were totaled to find the ultraviolet exposure time score. The top 25 ultraviolet exposure time scores in each age group were set as the high score group, and the bottom 25 ultraviolet exposure time scores were set as the low score group.
[0121] The skin brightness (L * The subjects were divided into low- and high-score groups for the UV exposure time score, and the skin brightness (L * ) were compared by age group. For those in their 20s, there was no difference between the low- and high-scoring groups in both the non-exposed part (arm) and the exposed part (cheek) ( Figure 2 A), on the other hand, for those in their 50s, there was no difference between the low-score group and the high-score group for the non-exposed part (arm), but for the exposed part (cheek), the skin brightness (L * ) significantly reduced ( Figure 2 B).
[0122] The moisture content of the stratum corneum in the exposed part (cheek) of the subjects was measured using a skin moisture tester Corneometer (Courage + Khazaka electronic GmbH). For those in their 20s, there was no correlation between the exposure time score and the moisture content of the stratum corneum in the exposed part (cheek), while for those in their 50s, there was an inverse correlation (Rs = -0.26) between the exposure time score and the moisture content of the stratum corneum in the exposed part (cheek). * )( Figure 3 ).
[0123] The skin viscoelasticity of the exposed part (cheek) was measured in the subjects using a skin viscoelasticity tester Cutometer MPA580 (Courage & Khazaka Electronic GmbH) [probe diameter (2 mm)]. For people in their 20s, there was no correlation between the exposure time score and skin viscoelasticity. On the other hand, for people in their 50s, there was a correlation between the exposure time score and skin viscoelasticity (Rs = 0.24), Rs = 0.25 ( Figure 4 ).
[0124] These results show that photoaging does not occur in non-exposed areas and that changes in appearance due to photoaging are not apparent in people in their 20s, whereas changes in appearance due to photoaging are apparent in people in their 50s, and that photoaging can be appropriately evaluated by the fraction of ultraviolet exposure time.
[0125] Example 2: UV scores based on lifestyle habits and UV exposure time scores Analysis of 9-HODE in the skin of subjects
[0126] For the subjects of Example 1, five cheek stratum corneum samples were collected from the same position using a keratometer (D-Squame) D100 [Promode].
[0127] Except for the top 1 stratum corneum sample, the remaining 4 stratum corneum samples were immersed in 3 mL of methanol and ultrasonically treated for 10 minutes. 3 mL of the ultrasonically treated extract was diluted 10 times with hydrochloric acid water (pH 1-3), loaded onto a hydrophobic column, washed with hexane, and purified / recovered with methyl formate. Then, after drying and solidification with nitrogen, it was dissolved in 30 μL of 70% methanol as an analytical sample. The 9-HODE amount was measured under the following analytical conditions.
[0128] Instrument: Nexera Liquid chromatograph (SHIMADZU), LCMS-8040 (SHIMADZU)
[0129] Ionization method: electrospray ionization (ESI)
[0130] Column: Waters XBridge C18 column (1.0x150mm, 3.5μm)
[0131] Column temperature: 30°C
[0132] Mobile phase: 0.1% acetic acid in water, acetonitrile: water = 4:1 (v / v)
[0133] In addition, protein quantification was performed using Micro BCA Protein Assay Kit (23235, Thermo Scientific).
[0134] The amount of 9-HODE present was normalized to the amount of protein and was determined. In Example 1, the amount of 9-HODE in the subjects in their 20s (N=17), 20s (N=14), 50s (N=13), and 50s (N=13) who were classified by the ultraviolet score based on lifestyle, and the amount of 9-HODE in the subjects in their 20s (N=23), 20s (N=22), 50s (N=22), and 50s (N=21) who were classified by the ultraviolet exposure time score were shown in the table. Figure 5 A and Figure 5 In B.
[0135] Example 3: Effects of 9-HODE in epidermal keratinocytes
[0136] Normal human keratinocytes were cultured at 8×10 4 Cells / mL were seeded in 24-well plates and cultured overnight at 37°C in a 5% CO2 atmosphere. On the second day of culture, 9-HODE (Cayman Chemical) was added at a final concentration of 10 μM, and culture was performed for 6, 24, and 48 hours. After culture, RNA was extracted using the RNeasy Mini Kit (QIAGEN), and reverse transcription was performed using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). The reverse transcribed nucleic acid was subjected to real-time PCR using the following TaqMan Gene Expression Assay (TaqMan gene expression assay) and TaqPath qPCR MasterMix, CG (Thermo Fisher Scientific), and StepOne plus real-time PCR system (Applied Biosystems), and the mRNA expression level was evaluated. The results are shown in Figure 6 The data without adding 9-HODE were used as the control.
[0137] Table 1
[0138] Primers Assay ID / TaqMan Gene Expression Assays GAPDH Hs02786624_g1 IL8 Hs00174103_m1 IL6 Hs00174131_m1 IL1α Hs00174092_m1 IL1β Hs01555410_m1 DKK1 Hs00183740_m1 GM-CSF Hs00929873_m1
[0139] Example 4: Effects of 9-HODE in cultured fibroblasts
[0140] Normal human fibroblasts were cultured at 4×10 4Cells / mL were seeded in 24-well plates and cultured overnight at 37°C in a 5% CO2 atmosphere. On the second day of culture, 9-HODE (Cayman Chcmical) was added at a final concentration of 10 μM, and cultured for 6, 24, and 48 hours. After culture, RNA was extracted using the RNeasy Mini Kit (QIAGEN), and reverse transcription was performed using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). The reverse transcribed nucleic acid was subjected to real-time PCR using the following TaqMan Gene Expression Assay and TaqPath qPCR MasterMix, CG (Thermo Fisher Scientific), and StepOne plus real-time PCR system (Applied Biosystems), and the mRNA expression level was evaluated. The results are shown in Figure 7 The data without 9-HODE addition were used as controls.
[0141] Table 2
[0142] Primers Assay ID / TaqMan Gene Expression Assays GAPDH Hs02786624_g1 MMP1 Hs00899658_m1 MMP3 Hs00968305_m1 COL1A1 Hs00164004_m1 COL3A1 Hs00943809_m1 IL8 Hs00174103_m1 IL1α Hs00174092_m1 Versican Hs00171642_m1 Decorin Hs00754870_s1
[0143] Example 5: Effect of the extract on 9-HODE (epidermal keratinocytes)
[0144] Normal human keratinocytes were cultured at 8×10 4 The cells / mL were seeded in a 24-well plate and cultured overnight at 37°C in a 5% CO2 atmosphere. On the second day of culture, the extract was added at a final concentration of 0.05 and 0.1%, and 9-HODE (Cayman Chemical) was added at a final concentration of 10 μM, and cultured for 24 hours. After culture, RNA was extracted using the RNeasy Mini Kit (QIAGEN) and reverse transcription was performed using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). The reverse transcribed nucleic acid was subjected to real-time PCR using the following primer set with Platinum SYBR Green qPCR SuperMix-UDG (Thermo Fisher Scientific) and StepOne plus real-time PCR system (Applied Biosystems), and the mRNA expression level was evaluated. The results are shown in Figure 8 The data without 9-HODE addition were used as controls.
[0145] Table 3
[0146] Primers Sequence (5' to 3') GAPDH_F GAAGGTGAAGGTCGGAGTC (sequence number 1) GAPDH_R GAAGATGGTGATGGGATTTC (serial number 2) GM-CSF_F ATGTGAATGCCATCCAGGAG (sequence number 3) GM-CSF_R TGTTTCATTCATCTCAGCAGCA (sequence number 4) DKK1_F CCTTGGATGGGTATTCCAGA (sequence number 5) DKK1_R CCTGAGGCACAGTCTGATGA (sequence number 6)
[0147] Example 6: Effect of the extract on 9-HODE (fibroblasts)
[0148] Normal human fibroblasts were cultured at 4×10 4 The cells / mL were seeded in a 24-well plate and cultured overnight at 37°C in a 5% CO2 atmosphere. On the second day of culture, the extract was added at a final concentration of 0.05 and 0.1%, and 9-HODE (Cayman Chemical) was added at a final concentration of 10 μM, and cultured for 48 hours. After culture, RNA was extracted using the RNeasy Mini Kit (QIAGEN), and reverse transcription was performed using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). The reverse transcribed nucleic acid was subjected to real-time PCR using the following primer set with Platinum SYBR Green qPCR SuperMix-UDG (Thermo Fisher Scientific), and StepOne plus real-time PCR system (Applied Biosystems), and the mRNA expression level was evaluated. The results are shown in Fig. 9 The data without 9-HODE addition were used as controls.
[0149] Table 4
[0150] Primers Sequence (5' to 3') GAPDH_F GAAGGTGAAGGTCGGAGTC (sequence number 1) GAPDH_R GAAGATGGTGATGGGATTTC (serial number 2) COL1A1_F GGGATTCCCTGGACCTAAAG (serial number 7) COL1A1_R GGAACACCTCGCTCTCCA (sequence number 8) COL3A1_F TGGTCTGCAAGGAATGCCTGGA (sequence number 9) COL3A1_R TCTTTCCCTGGGACACCATCAG (serial number 1o) DCN_F CCTGATGACCGCGACTTCGAG (sequence number 11) DCN_R TTTGGCACTTTGTCCAGACCC (serial number 12) VCAN_F ACGGGATTGAAGACACACAAG (serial number 13) VCAN_R AGCCTCAAAATTCAGTGTGTA (serial number 14)
Claims
1. A method for evaluating photoaging of skin, It is characterized in that The amount of 9-HODE in the skin was determined.
2. The method according to claim 1, wherein the photoaging of the skin is at least one selected from dullness, spots, chronic inflammation, wrinkles, decreased skin moisture retention function and sagging.
3. A method for screening photoaging regulators, It is characterized in that An agent that can regulate the production amount or function of 9-HODE derived from the skin is selected.
4. The method according to claim 3, wherein the photoaging of the skin is at least one selected from the group consisting of dullness, spots, chronic inflammation, wrinkles, decreased skin moisture retention function, and sagging.
5. The screening method according to claim 3, comprising the following steps: A step of culturing skin cells with a culture medium containing a candidate ingredient; A step of measuring the amount of 9-HODE in cultured skin cells; and The step of comparing the measured 9-HODE amount with the 9-HODE amount of the control, In the case where the amount of 9-HODE is increased or decreased, candidate ingredients are screened as photoaging regulators.
6. The method according to claim 3, wherein the operation of selecting an agent capable of regulating the production amount or function of the 9-HODE is an operation of measuring the increase or decrease in the expression of at least one protein or gene selected from IL1A, IL1B, IL6, IL8, GM-CSF, DKK1, COL1A1, COL3A1, MMP1, MMP3, VCAN and DCN caused by the addition of 9-HODE.
7. The screening method according to claim 6, comprising the following steps: A step of culturing skin cells using a culture medium containing a candidate ingredient and 9-HODE; A step of measuring the amount of at least one protein selected from the group consisting of IL1A, IL1B, IL6, IL8, GM-CSF, DKK1, COL1A1, COL3A1, MMP1, MMP3, VCAN and DCN or the expression level of the gene in the cultured skin cells or the culture supernatant; and a step of comparing the amount of protein or the expression level of gene in cells or culture supernatant cultured in a medium not containing the candidate component with the amount of protein or the expression level of gene in cells or culture supernatant cultured in a medium containing the candidate component as a control, When the amount of protein or the expression level of gene in cells or culture supernatants cultured with a medium containing the candidate ingredient increases or decreases, the candidate ingredient is screened as a photoaging regulator.
8. Use of a component that inhibits the production amount or function of 9-HODE in the manufacture of a photoaging inhibitor.
9. The use according to claim 8, wherein the component that regulates the function of 9-HODE is a GPR132 (G2A) antagonist.
10. The use according to claim 9, wherein the component for regulating the production amount or function of 9-HODE is tea extract or Potentilla officinalis root extract.
11. A component for regulating the production amount or function of 9-HODE, or use of 9-HODE for producing a bone density improving agent.
